EUCTR2013-000918-37-BE进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndromes (MDS)SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine - Phase III study of eltrombopag in advanced MDS subjects receiving azacitidine treatment
GlaxoSmithKline Research and Development Ltd0 个研究点目标入组 350 人开始时间: 2014年7月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for enrolment in the study must meet all of the following criteria. The eligibility criteria are to be met during the screening period, defined as the period up to 28 days prior to randomization on Day 1. Informed consent may be obtained >28 days before Day 1, if required, to allow time for receipt of cytogenetic results.
- •1. Age = 18 years. (For subjects in Taiwan, Age = 20 years).
- •2. MDS by World Health Organization (WHO) or French-American-British (FAB) classification.
- •3. Intermediate 1, intermediate 2 or high risk MDS by IPSS.
- •A bone marrow for the determination of IPSS must be completed during the screening period, or within 3 months prior to randomization. Assessment of bone marrow blasts must be completed by bone marrow slide review.
- •4. At least one platelet count < 75 Gi/L.
- •5. Eastern Cooperative Oncology Group (ECOG) Status 0-2.
- •6. Adequate baseline organ function defined by the criteria below
- •total bilirubin less than 1.5x the upper limit of normal (ULN) except for Gilbert’s syndrome or cases clearly not indicative of inadequate liver function (i.e. elevation of indirect [haemolytic] bilirubin in the absence of ALT abnormality)
- •alanine aminotransferase (ALT) = 2.5xULN
- •creatinine = 2.5xULN
- •7. Subjects with a QTc <450msec or <480msec for subjects with bundle branch block.
- •The QTc is the QT interval corrected for heart rate according to Fridericia’s formula (QTcF), machine or manual overread.
- •For subject eligibility and withdrawal, QTcF will be used.
- •For purposes of data analysis, QTcF will be used.
- •The QTc should be based on single or averaged QTc values of triplicate
- •electrocardiograms (ECGs) obtained over a brief recording period
- •8. Subject is able to understand and comply with protocol requirements and instructions.
- •9. Subject has signed and dated informed consent.
- •10. Women must be either of non-child bearing potential, or women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study.
- •11. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception
- •(as defined in Section 7.3.3) during the study and for 3 months following the last dose of study treatment.
- •12. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception (as described in Section 7.3.3) from time of randomization until 16 weeks after the last dose of study treatment.
- •13. French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 158
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 192
排除标准
- •Subjects meeting any of the following criteria at the time of randomization must not be enrolled in the study:
- •1. Previous treatment with hypomethylating agent or induction chemotherapy for MDS.
- •2. Proliferative type chronic myelomonocytic leukemia with white blood cell count >12 Gi/L at any time during the 28 days before Day 1.
- •3. History of treatment with eltrombopag, romiplostim or other TPO-R agonists.
- •4. Previous allogeneic stem-cell transplantation.
- •5. Known thrombophilic risk factors. Exception: Subjects for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator.
- •6. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of investigational product (eltrombopag/placebo).
- •7. Active and uncontrolled infections, including hepatitis B or C.
- •8. Human Immunodeficiency Virus (HIV) infection.
- •9. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or its excipient, or azacitidine, that contraindicates the subjects’ participation.
- •10. Pregnant or lactating female.
- •11. Any serious and/or unstable pre-existing medical (including any advanced malignancy other than the disease under study), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance with the study procedures.
- •12. French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days.
研究者
相似试验
进行中（未招募）
1 期
16-week efficacy and 2-year safety, tolerability and efficacy of secukinumab in participants with active ankylosing spondylitisAnkylosing SpondylitisEUCTR2013-005575-41-CZovartis Pharma Services AG350
进行中（未招募）
1 期
Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjectsEUCTR2018-001547-32-ATovartis Pharma AG673
进行中（未招募）
1 期
A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge ModelTreatment of InfluenzaMedDRA version: 20.1 Level: LLT Classification code 10022002 Term: Influenza A virus infection System Organ Class: 100000004862MedDRA version: 20.0 Level: LLT Classification code 10022001 Term: Influenza (epidemic) System Organ Class: 100000004862MedDRA version: 20.0 Level: LLT Classification code 10016790 Term: Flu System Organ Class: 100000004862EUCTR2013-001983-52-GBGenentech Inc.101
进行中（未招募）
1 期
Study of efficacy and safety of canakinumab in combination with docetaxel in subjects with non-small cell lung cancers as a second or third line therapy.on-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002480-26-GRovartis Pharma AG244
进行中（未招募）
1 期
Study of safety and efficacy of PDR001 in combination with dabrafenib and trametinib in patients with a genetically distinct subtype of unresectable or metastatic melanoma, which is characterised by a mutation in the BRAF geneEUCTR2016-002794-35-DEovartis Pharma AG538